Salicylic acid: old and new implications for the treatment of type 2 diabetes? by Graham Rena & Kei Sakamoto
REVIEW ARTICLE
Salicylic acid: old and new implications for the treatment
of type 2 diabetes?
Graham Rena • Kei Sakamoto
Received: 1 May 2014 / Accepted: 14 May 2014 / Published online: 12 June 2014
 The Japan Diabetes Society 2014
Abstract Efficacy of salicylic acid as a treatment for
diabetes was first established well over a century ago.
Antihyperglycaemic effects are thought to include
improved peripheral insulin sensitivity and suppression of
hepatic glucose production. For most of this period, the
molecular mechanisms underlying these effects have been
poorly understood and these are still a focus of consider-
able research, which is reviewed here. Antihyperglycaemic
effects are observed only at much higher concentrations
than analgesic, antipyretic and antithrombotic properties,
suggesting that different targets underlie the antidiabetic
aspects of salicylate pharmacology. In the 1950s, antihy-
perglycaemic responses were linked to mitochondrial
uncoupling effects of the drug. Then at the beginning of
this century, antihyperglycaemic effects were linked to
anti-inflammatory effects of the drug on NF-jB signalling.
More recently, new work suggests that direct activation of
AMPK may contribute to antihyperglycaemic/anti-
hyperlipidemic actions of salicylates. Better understanding
of the mechanism of salicylate’s anthyperglycaemic effects
may ultimately accelerate the development of new drugs
for human use.
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Ancient and early studies
Empirical therapeutic use of naturally occurring salicylate-
like compounds, abundant in plants such as myrtle and
willow [1], has been ongoing since the early days of civi-
lization in most parts of the world. For example, use of the
willow is included in many early medical texts, including a
Sumerian tablet dated to the third millennium B.C.E. [2].
Even though the active agent was unknown until much
later, some of the early applications suggested for salicy-
late-containing plants were appropriate by modern stan-
dards. The Edwin Smith Surgical Papyrus from ancient
Egypt [3] recommends use of willow leaves as ‘a cool
medium for drawing the warmth,’ when a wound ‘is
inflamed, with a concentration of warmth spewing from the
mouth of that wound, and the lips of the wound are ruddy
[red] and when that man is feverish from it.’ The text
illustrates not only that some of the cardinal signs of
inflammation were recognized, but also suggests that anti-
inflammatory/anti-septic properties of willow were known
[3]. Another text, The Hearst Medical Papyrus, recom-
mends willow to ‘cool’ chronic inflammation likely to be
arthritis or rheumatism [4]. By the time of ancient Greece
and Rome, salicylate-containing plants were used for their
analgesic, keratolytic, anti-inflammatory and antiseptic
properties [5–7].
In the nineteenth century, there were significant
advances in the development of the salicylates as drugs.
It became possible to isolate salicylate-related active
agents such as salicin from plant extracts [7] and study
them clinically. Perhaps the first such (uncontrolled)
study was performed by MacLagan, a Dundee physician,
who established that salicin, which is converted to
salicylate, is a useful treatment for rheumatic fever [8].
Alongside this work on the natural products, Kolbe and
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Lauteman devised a chemical synthesis of salicylate that
is still used today [6, 7], enabling salicylate to be syn-
thesized in increasing quantities and allowing the ther-
apeutic effects of this drug to be studied in isolation for
the first time. At about the same time as MacLagan’s
work on salicin, for example, Stricker reported that
salicylate was also an effective treatment for rheumatic
fever [9].
Salicylate itself is used little today and one of the main
reasons for this is the identification by Bayer of a superior
compound, acetylsalicylic acid (aspirin) [7]. This agent
largely replaced salicylate use in the clinic and went on to
become one of the most widely used medications.
Mechanisms of action of salicylate and aspirin only began
to be established much later, once the intracellular targets
of the drug were studied, culminating in Vane sharing the
Nobel prize for the discovery that aspirin blocks the
formation of arachidonic acid-derived inflammatory
mediators [10].
In relation to diabetes, antihyperglycaemic effects of
salicylate began to be reported in the 1870s. Gross and
Greenberg covered this early period well in their com-
prehensive monograph published in 1948 [6]. Starting
with the work of Ebstein [11] and including the first
detailed English-language account by Williamson in
1901 [12], they cite 15 clinical reports of antihypergly-
caemic effects of salicylate [6]; however, at the time
they were writing, Gross and Greenberg reported that
this use had long since been discontinued. Indepen-
dently, the effect was in the process of being rediscov-
ered experimentally, when it was found that aspirin,
which is metabolized to salicylate [6, 13], was capable of
inducing antihyperglycaemic effects in partly depan-
creatised animals [14]. Salicylate was also effective in
alleviating hyperglycaemia following alloxan treatment
[15]. In the same decade, Reid, MacDougall and
Andrews correctly deduced and then investigated similar
actions in humans, when confronted with unexpected
normoglycemia in a known diabetes patient who was
taking only aspirin as part of a rheumatic fever trial [13].
These early studies established not only that larger
(gram) quantities of the drugs were required than were
necessary for analgesic/antipyretic effects [6, 12–14],
but also that salicylate did not induce hypoglycaemia
[13]. Unfortunately, at the doses used, the beneficial
effects of salicylate were accompanied by serious side
effects, including persistent nausea, vomiting, tinnitus
and deafness [13]. The nausea and vomiting in particular
could in turn give rise to starvation ketosis, which was
hard to distinguish from diabetic ketosis and which was
thought to have accounted for the salicylates’ abandon-
ment in clinical use [16].
Effects on mitochondrial function/ATP production
The rediscovery in the 1950s of salicylate’s effects on
glucose metabolism prompted investigation of the mecha-
nism. One study found increased oxygen consumption in
humans given doses either of 10 g salicylate intravenously
or 7.5–10 g aspirin orally [17]. Elevation of oxygen con-
sumption was also observed in rats [18] and rat diaphragm
[19]. Shortly afterwards, using tissues and isolated mito-
chondria, it was found that salicylate uncoupled oxygen
consumption from generation of ATP [20–22]. The effects
of salicylate on metabolism were qualitatively similar to
the uncoupler 2,4 dinitrophenol (DNP), in that both drugs
increased oxygen consumption and glycogen breakdown,
while decreasing ATP production [19–26]. In addition,
effects of salicylate on mitochondrial oxygen production
correlated well with antihyperglycaemic effects, because
neither property was shared by other hydroxybenzoate
analogues of the drug, such as 2,5 diHBA (also known as
gentisate) and 2,6 diHBA (also known as c-resorcylate)
[15, 27, 28]. In tissues, it was found that salicylate and
DNP increased glucose uptake in isolated rat diaphragm
and heart muscle [29–31], while later studies in perfused
liver found that salicylate inhibited hepatic gluconeogen-
esis [32]. More recent work on aspirin used clamps and
glucose tracers to study whole body glucose disposal.
These studies confirmed that blood glucose is lowered
through a combination of reduced hepatic glucose pro-
duction and elevated glucose uptake [33].
The work just described led to the notion that the anti-
hyperglycaemic effects of salicylate were related to its
uncoupling properties [22, 34]. However, other data led
some to wonder as to whether mitochondrial inhibition
contributed more to salicylate’s side-effects than its ther-
apeutic responses [21, 35]. DNP had for example briefly
been used earlier in humans as a crude weight loss agent,
but its use was stopped when it was found to eliminate ‘‘not
only the fat but also the patients’’ [36]. Moreover, in
comparative clinical investigation of salicylate and DNP,
Reid found that DNP in equivalent dosage had significantly
lower effects on blood sugar than aspirin [35], concluding
his study by posing the question: ‘‘Is it enough to say that
the fundamental action of both DNP and salicylate is
inhibition of oxidative phosphorylation without further
specification to account for quantitative differences?’’ [35].
In some respects, this debate and the wider concept of
mitochondrial inhibition as both a therapeutic and toxic
mechanism, is strikingly reminiscent of discussion around
metformin action, where inhibition of mitochondrial ATP
production by large doses of the drug is thought to account
not only for antihyperglycaemic effects, but also side-
effects of the drug such as lactic acidosis [37–40]. Lack of
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hypoglycaemia is another aspect common to both drug
types [13, 38]. It is important to note, however, that
although both drug classes suppress mitochondrial ATP
production, the mitochondrial targets of salicylates and
biguanides are different. As described above, salicylate is
thought to act on the mitochondria in a similar manner to
DNP, which is now known to uncouple mitochondrial ATP
production from oxygen consumption by collapsing the
proton gradient that couples these two processes. Unlike
DNP, biguanides are not true uncouplers because they
suppress both ATP production and oxygen consumption by
action on the electron transport chain [37, 38, 41].
Effects on pro-inflammatory IKK-NF-jB signalling
The first significant enzyme targets of salicylates to be
identified were the cyclooxygenase (COX) enzymes,
important anti-inflammatory targets of both salicylate and
aspirin. In the body, aspirin is rapidly converted to
salicylate [42]; however, aspirin does not act simply as a
prodrug of salicylate, as aspirin but not salicylate acety-
lates biomolecules [43]. This property includes irrevers-
ible and potent inhibition of COX enzymes through
acetylation of an active-site serine [44]. Inhibition of
COX-1 in platelets probably accounts for the antithrom-
botic effect of aspirin to suppress platelet aggregation
biomolecules [43]. Salicylate also inhibits COX enzymes
less potently by a less well understood mechanism [45];
however, inhibition of COX by either drug occurs at
much lower concentrations than are required to elicit
antihyperglycaemic effects, suggesting that this aspect of
their pharmacology depends on different targets. The first
such targets to be proposed followed discovery of salic-
ylate and aspirin’s inhibitory effects on inflammatory NF-
jB signalling (Figs. 1, 2).
Numerous metabolic stresses that induce insulin resis-
tance and type 2 diabetes stimulate inflammation- and
stress-induced kinases such as IjB kinase-b (IKKb). IKKb
activates transcription factor nuclear factor jB (NF-jB),
and obesity is associated with induction of the expression
of NF-jB target genes, such as proinflammatory cytokines,
including TNF [46], IL-6 [46, 47] and IL-1b [48] in mul-
tiple tissues/organs such as liver and adipose. Salicylate
suppresses NF-jB signalling [49, 50], apparently by
inhibiting IKKb, which has been detected in cells and in
cell-free experiments [51]. Aspirin and salicylate are both
reported to be effective inhibitors of IKKb in cell-free
experiments [51]. However, these findings need to be
interpreted with caution, because more recent kinase pro-
filing experiments published online suggest that salicylate
inhibits around 75 % of kinases tested at least as potently
as it effects IKKb. Further investigation linked NF-jB to
antihyperglycaemic effects of salicylate in obese mouse
models, on the basis that genetic knockout of the IKKb
gene produced similar effects to salicylate, protecting
against the development of insulin resistance during high
fat feeding and in obese ob/ob mice [52].
To understand these effects in more detail, additional
experiments found that either salicylate or genetic knock-
out of the IKKb gene prevented lipid-induced insulin
resistance, with salicylate normalising skeletal muscle
glucose uptake in lipid-infused animals [53]. This sup-
ported the idea, reviewed excellently elsewhere [54], that
salicylate treats type 2 diabetes at least in part by reducing
obesity-dependent chronic inflammation. Tissue-specific
knockouts of IKKb enabled the contribution of individual
organs to be assessed. Blockade of NF-jB signalling in
liver cells was sufficient to preserve insulin sensitivity in
the liver, but obesity still induced insulin resistance in other
tissues [55]. In contrast, blockade of NF-jB signalling in
myeloid cells protected animals from systemic insulin
resistance, underlining the potential importance of inflam-
matory cell NF-jB in development of obesity-induced
insulin resistance [55]. Data from genetic models is con-
sistent with this concept of salicylate treating diabetes due
to its ability to reverse chronic inflammation. In these
studies, low-level genetic overexpression of NF-jB in the
liver resulted in type 2 diabetes that could be improved by
salicylate, and which was reversed in mice co-expressing
the IjB repressor protein [56].
Fig. 1 Structures of salicylic acid and related compounds
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Clinical trials
Given the side effects associated with high-dose salicylate
and aspirin, several clinical trials of a salicylate dimer
known as salsalate have been carried out on obese non-
diabetic subjects [57, 58], those with insulin resistance
[59], and most recently, with type 2 diabetes [60]. An
initial 12-week study using salsalate in patients with type 2
diabetes showed decreased fasting blood glucose,
decreased fasting non-esterified fatty acids and increased
adipokine expression; however, glucose clearance did not
change. Salsalate appears to be well tolerated within the
doses used, but side effects such as tinnitus and mild gas-
trointestinal disturbance were above control groups [59,
60]. In diabetic subjects salsalate caused slight suppression
of NF-jB in subcutaneous abdominal adipose tissue when
used at a typical maximum dose of 4 g/day [60], but in
another study there was no effect on NF-jB in peripheral
blood mononuclear cells from patients given 3 g/day [57].
The modest effects on NF-jB and glucose clearance might
be explained by the fact that the doses of salsalate were
lower [57, 60] and/or shorter [57] than the previous work
with aspirin (which was used at 7 g/day for 2 weeks [33]).
Salsalate may work at least in part by increasing insulin
concentrations, and in this respect salicylate definitely
seems to be different from metformin, but such effects may
be modest, as hypoglycaemia was only observed in patients
also taking a sulfonylurea [57, 59]. Another interesting
difference compared with the earlier work on aspirin is that
salsalate did not significantly increase peripheral insulin
sensitivity [33, 57, 60]. Consistent with this, salicylate
inhibits NF-jB activity in liver more readily than in mus-
cle, at least in rodents [56]. This suggests that at these
intermediate doses, suppression of hepatic glucose pro-
duction may be more significant than improvements in
peripheral insulin sensitivity. The greater significance of
hepatic glucose production at lower concentrations of drug
is again highly reminiscent of the action of biguanides [37,
38].
Effects on AMPK, a key energy sensor and regulator
Recent studies have unexpectedly demonstrated that AMP-
activated protein kinase (AMPK) is activated by salicylate
[61] or aspirin [62] in cultured cells. AMPK is a key cel-
lular energy sensor and regulator of energy homeostasis
that coordinates metabolic pathways in order to balance
nutrient supply with energy demand. AMPK is activated by
various energy stresses that increase intracellular ADP-to-
ATP and AMP-to-ATP ratios, either by promoting ATP
consumption (e.g., via muscle contraction) or by reducing
ATP generation (e.g., via hypoxia, mitochondrial poison-
ing) [63, 64]. Once activated, AMPK functions to restore
Fig. 2 Schematic illustration of likely antidiabetic targets of salic-
ylate. Salicylate acts on various cells/tissues. In hepatocytes, salic-
ylate (higher concentration [ 3 mM]) inhibits mitochondrial ATP
production, leading to an increase in AMP/ATP ratio, which
stimulates AMPK and also would be expected to suppress glucose
production via multiple inhibitory effects on gluconeogenic pathways.
Salicylate at lower concentrations (B 3 mM) directly binds and
stimulates AMPK. AMPK activation leads to stimulation of fatty acid
oxidation and inhibition of lipid synthetic pathways, which would be
expected to ameliorate insulin resistance caused by lipotoxicity.
Salicylate also inhibits pro-inflammatory responses (e.g., gene
expression) through suppression of the NF-jB pathway
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energy balance by accelerating ATP production pathways
(e.g., glucose uptake, fatty acid oxidation), while simulta-
neously suppressing ATP utilization pathways (e.g., lipid,
protein synthesis). Because AMPK activation (e.g., by
exercise) brings about beneficial physiological outcomes
that ameliorate metabolic dysfunctions by improving gly-
caemic control and plasma lipid profiles, AMPK is con-
sidered as a major drug target aimed at treating or delaying
the onset of metabolic diseases such as type 2 diabetes
[65].
AMPK is a heterotrimeric complex containing a cata-
lytic subunit (a) and two regulatory subunits (b, c). Two
isoforms of the a- and b-subunits exist (a1, a2, b1, b2),
whereas there are three isoforms of the c-subunit (c1, c2,
c3) [63]. Isoform expression varies among cell types (and
also species). AMPK is activated by upstream kinases
LKB1 and Ca2?-/calmodulin-dependent protein kinase
kinase b (CaMKKb) via phosphorylation of Thr172 on the
a catalytic subunit. AMP binding to the c-subunit allos-
terically stimulates AMPK, and ADP and/or AMP binding
promotes Thr172 phosphorylation and protects it against
dephosphorylation by protein phosphatase(s), while ATP
competes for binding at the same sites and antagonizes the
effects of AMP [64].
In a recent work [61], Hardie and colleagues initially
demonstrated that salicylate at concentrations higher than
1 mM stimulated AMPK in HEK293 cells. However, given
that a variety of compounds including anti-diabetic drugs
(e.g., metformin) and xenobiotics (which are implicated to
elicit anti-obesity/diabetic effects such as resveratrol and
berberine) activate AMPK in an indirect mechanism by
depleting cellular energy levels (i.e., by increasing AMP-
to-ATP ratio via suppression of mitochondrial respiration)
[61], it was perhaps not unexpected that salicylate would
be another indirect activator. Interestingly, salicylate acti-
vated AMPK in an AMP/ADP-independent manner when
treated with concentrations below 10 mM in intact cells
[61]. Subsequently, Hardie and colleagues demonstrated
[61] that salicylate directly activated recombinant/purified
AMPKabc complex in a cell-free assay and was found to
bind at the same site as A769662, a small molecule syn-
thetic activator originally identified by Abbott [66]. Indeed,
both A769662 and salicylate activate AMPK via allosteric
action, and also protect active (phosphorylated) AMPKa at
Thr172 from dephosphorylation through interacting with
the AMPKb1-subunit [67]. To determine if salicylate-
dependent activation of AMPK had any physiological
implications, Hardie and colleagues treated primary hepa-
tocytes with salicylate and observed that it activated
AMPK, increased acetyl CoA carboxylase (ACC) phos-
phorylation (a well characterized AMPK substrate involved
in lipid oxidation (ACC2) and synthesis (ACC1)) [68], and
fatty acid oxidation in wild-type, but not in AMPKb1-
knockout mice [61]. Moreover, administration of salicylate
stimulated fat oxidation (as assessed by measuring the
respiratory exchange ratio) in vivo in wild-type, and this
effect was abolished in the AMPKb1-knockout mice [61].
These results verify that the increases in whole-body fat
oxidation induced by salicylate were mediated through
AMPK activation.
Concentrations of 1–3 mM that were shown to activate
AMPK in intact cells [61] are readily reached in the plasma
of humans with high doses of either aspirin or salsalate [33,
58, 69]. Recent studies in both rodents and human clinical
trials showed that salicylate (mainly its pro-drugs such as
salsalate and aspirin) significantly reduced circulating free
fatty acids and/or triglycerides in obese/hyperlipidemic
rodents [70] and humans with type 2 diabetes [57–60].
These alterations in lipid metabolism are often seen prior to
any improvements in insulin sensitivity; therefore, it is
tempting to speculate that these lipid-lowering effects by
salicylate (or its pro-drugs) might be due the consequences
of AMPK activation. However, a long-term salicylate
treatment (12 weeks, 250 mg/kg i.p.) in high-fat diet
(HFD)-fed wild-type and AMPKb1-knockout mice showed
similar protective effects against HFD-induced insulin
resistance and glucose intolerance, indicating that effects
on AMPK-independent pathways (such as IKK-NFjB)
play an important role in the improvement in insulin sen-
sitivity [61]. In addition, the study did not provide detailed
metabolic analysis (e.g., lipid metabolism and inflamma-
tory markers), and it would be interesting to compare these
parameters between wild-type and AMPKb1-knockout
mice. Finally, it should also be noted that one study has
shown that although b1 is the predominant b isoform in
mouse liver, b2 appears to be predominant in human
hepatocytes [71]. Given that salicylate stimulates b1-con-
taining complex, but not b2, this needs to be revisited and
clarified in humans (for example, by using primary
hepatocytes).
Concluding remarks
Over 60 years after Reid wondered whether uncoupling
properties were really enough to account for the antihy-
perglycaemic action of salicylate, work in this area has
discovered two major additional mechanisms that may
contribute towards the improved therapeutic efficacy of
this drug over simpler uncouplers. At the high antihyper-
glycaemic doses of salicylate that promote uncoupling, this
drug also regulates NF-jB and directly activates AMPK
in vivo. Emerging clinical data suggest that at intermediate
well-tolerated doses, effects on hepatic glucose production
may be more significant than those on peripheral insulin
sensitivity. Further targeted studies to determine the overall
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contribution of uncoupling, NF-jB, and direct AMPK
regulation on each of these antihyperglycaemic physio-
logical responses (as well as anti-inflammatory and anti-
proliferative/-cancer effects [69]) will allow a deeper
understanding of salicylate action to develop.
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